Table 4.
Comparison of oral rotavirus vaccines
| Rotavirus Vaccines | Rotarix® (GSK) [100] | RotaTeq® (Merck) [100] | Rotavac® (Bharat Biotech) [112] | RotaSIIL® (Serum) [116] | Rotavin (Polyvac) [120] | LLR (Lanzhou) [118, 119] | RV3-BB (Bio Farma) [121] |
|---|---|---|---|---|---|---|---|
| Licensure | Several countries, 2006 | Several countries, 2006 | India, 2014 | India, 2017 | Vietnam, 2012 | China, 2000 | Clinical trial phase IIb |
| Prequalification | Yes | Yes | Yes | Yes | No | No | No |
| Strains | Monovalent, human derived G1P[8] | Pentavalent, WC3 G6P[5] bovine reassortant G1–4,P8 | Monovalent, human neonatal derived G9P[11] | Pentavalent, UK Bovine G6P[5], reassortant G1–4, G9 | Monovalent, human G1P[8] | Monovalent, Lamb G10P[12] | Monovalent, human neonatal G3P[6] |
| Number of doses | 2 | 3 | 3 | 3 | 2 | 3 | 3 |
| Age, first dose | 6 weeks | 6 weeks | 6 weeks | 6 weeks | 6 weeks | 2 months | New born: 0–5 days Infant: 8 weeks |
| Age, last dose | 10 weeks | 14 weeks | 14 weeks | 14 weeks | 14 weeks | 36 months | New born: 14 week Infant: 18 weeks |
| Dosage | 106 median CCID50 of live attenuated human G1P[8] RV | 2.0–2.8 × 106 infectious units per reassortant | 105 fluorescent focus unit (FFU) of live rotavirus | 105.6 infectious units per reassortant | 106.3 FFU/dose of live attenuated human G1P[8] particles | > 5.5 log CCID50 | 8.3–8.7 × 106 FCFU/ml |
| UNICEF price per course for GAVI-supported countries, 2020 [122] | $4.58 | $9.60 (RotaTeq is no longer an option available to GAVI-supported countries) | $2.55 | $4.65 (1-dose vial) $2.85 (2-dose vial) | $17.60 | $72 for the three-dose series |